Sansure Biotech (SHSE:688289) EBIT: ¥152 Mil (TTM As of Mar. 2026)


SHSE:688289 Sansure Biotech Inc SHSE:688289
67 GF Score
Price ¥14.73
GF Value ¥20.52
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Sansure Biotech EBIT?

Sansure Biotech SHSE:688289 +4.32% 67 EBIT is ¥152 Mil as of Mar. 2026. GuruFocus rates SHSE:688289 with a GF Score™ of 67/100 and a GF Value™ of ¥20.52 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Sansure Biotech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥58 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥152 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sansure Biotech's annualized ROC % for the quarter that ended in Mar. 2026 was 3.96%. Sansure Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 16.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sansure Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.59%.


Sansure Biotech  (SHSE:688289) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sansure Biotech's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=240.048 * ( 1 - 18.24% )/( (4842.992 + 5078.72)/ 2 )
=196.2632448/4960.856
=3.96 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9526.68 - 615.468 - ( 4125.413 - max(0, 1206.017 - 5274.237+4125.413))
=4842.992

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9606.771 - 605.078 - ( 3922.973 - max(0, 1210.639 - 5160.631+3922.973))
=5078.72

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sansure Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=230.836/( ( (1334.927 + max(55.12, 0)) + (1323.432 + max(146.786, 0)) )/ 2 )
=230.836/( ( 1390.047 + 1470.218 )/ 2 )
=230.836/1430.1325
=16.14 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(621.444 + 413.691 + 77.150000000001) - (615.468 + 0 + 441.697)
=55.12

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(668.073 + 443.038 + 82.407) - (605.078 + 0 + 441.654)
=146.786

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sansure Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=151.671/5857.630
=2.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sansure Biotech EBIT Related Terms


Sansure Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Sansure Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sansure Biotech EBIT Chart

Sansure Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only 2,617.04 2,318.01 412.89 279.01 199.21

Sansure Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.25 76.58 15.52 1.87 57.71

SHSE:688289 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Sansure Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sansure Biotech EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sansure Biotech's EV-to-EBIT falls into.


SHSE:688289
67GF Score
Sansure Biotech Inc SHSE:688289
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sansure Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥152 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥152 Mil mean?
Sansure Biotech (SHSE:688289) has a EBIT of ¥152 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sansure Biotech.
Is Sansure Biotech's EBIT too high?
Sansure Biotech's current EBIT is ¥152 Mil. Overall, Sansure Biotech has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's EBIT compare to ISRG and BDX?
Sansure Biotech's EBIT of ¥152 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sansure Biotech. Sansure Biotech's current EBIT is ¥152 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.52, compared to a current price of ¥14.73 — trading 28.2% below its estimated fair value. The current EBIT is ¥152 Mil. Sansure Biotech's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current EBIT is ¥152 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sansure Biotech (SHSE:688289) Overvalued in 2026?

Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued. The current stock price of ¥14.73 is trading 28.2% below its estimated GF Value™ of ¥20.52. GuruFocus considers Sansure Biotech to be Modestly Undervalued.

Key valuation signals for SHSE:688289:

  • EBIT: ¥152 Mil
  • GF Value™: ¥20.52 vs. price of ¥14.73 (28.2% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sansure Biotech Business Description

Address No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205
Sansure Biotech Inc is engaged in the Research, development, production, and sales of diagnostic reagents and instruments.
67GF Score

Get the complete analysis for SHSE:688289

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.73
Price
¥20.52
GF Value